<html>
<head>
<META http-equiv="Content-Type" content="text/html; charset=UTF-8">
<title>NCT00645515 on 2008_04_02: ClinicalTrials.gov Archive</title>
<link rel="stylesheet" href="/archive/history.css">
<link rel="stylesheet" href="/archive/received.css">
</head>
<body class="received">
<div class="navTop"><table class="navTopTriptych"><tr><td class="navTopTriptychL"><img src="/archive/ctgov_logo_ttl.gif" alt="ClinicalTrials.gov" width="360" height="47" /></td><td class="navTopTriptychC" style="background-image: url(/archive/ctgov_logo_ttm.gif)" /><td class="navTopTriptychR"><img src="/archive/ctgov_logo_ttr.gif" alt="Linking patients to medical research" width="314" height="47" /></td></tr></table></div>
<div id="navLinks" class="navLinks"><a href="/archive/NCT00645515">&#8592; History of this study</a><a href="http://clinicaltrials.gov/show/NCT00645515">&#8593; Current version of this study</a></div><h1>View of NCT00645515 on
  2008_04_02</h1>
<table class="info">
<tr>
<th nowrap>ClinicalTrials Identifier:</th><td>NCT00645515</td>
</tr>
<tr>
<th>Updated:</th><td>2008_04_02</td>
</tr>
<tr>
<th class="section" colspan="2">
<h2>Descriptive Information</h2>
</th>
</tr>
<tr>
<th>Brief title</th><td>
<p>A Study Comparing the Safety and Efficacy of Ziprasidone and Risperidone for the Treatment of Chronic Schizophrenia</p>
</td>
</tr>
<tr>
<th>Official title</th><td>
<p>Ziprasidone Versus Risperidone In The Treatment Of Chronic Schizophrenia: A Six Months, Double Blind Randomized, Parallel Group Study</p>
</td>
</tr>
<tr>
<th>Brief summary</th>
</tr>
<tr>
<td colspan="2" class="bigdent">
<p>The purpose of this study is to compare the safety of ziprasidone and risperidone for the treatment of chronic schizophrenia. &nbsp;The primary purpose is to differentiate the effects of ziprasidone and risperidone on extrapyramidal side effects and the secondary purpose is to compare their tolerability and efficacy.</p>
</td>
</tr>
<tr>
<th>Detailed description</th>
</tr>
<tr>
<td colspan="2" class="bigdent">
<p></p>
</td>
</tr>
<tr>
<th>Phase</th><td>Phase 3</td>
</tr>
<tr>
<th>Study type</th><td>Interventional</td>
</tr>
<tr>
<th>Study design</th><td>Treatment</td>
</tr>
<tr>
<th>Study design</th><td>Randomized</td>
</tr>
<tr>
<th>Study design</th><td>Double Blind (Subject, Investigator)</td>
</tr>
<tr>
<th>Study design</th><td>Parallel Assignment</td>
</tr>
<tr>
<th>Study design</th><td>Safety/Efficacy Study</td>
</tr>
<tr>
<th>Primary outcome</th><td>Measure: Change from baseline in Simpson-Angus Scale (SAS) scores at Weeks 1, 2, 3, 4, 6, 10, 12, 16, and 24<br>Time Frame: Day 1 and Weeks 1, 2, 3, 4, 6, 10, 12, 16, and 24<br>Safety Issue? No</td>
</tr>
<tr>
<th>Secondary outcome</th><td>Measure: Change from baseline in cognitive function assessment at Weeks 4 and 24<br>Time Frame: Day 1 and Weeks 4 and 24<br>Safety Issue? No</td>
</tr>
<tr>
<th>Secondary outcome</th><td>Measure: Change from baseline in Patient Preference Scale (PPS) at Weeks 4, 10, 12, 16, and 24<br>Time Frame: Day 1 and Weeks 4, 10, 12, 16, and 24<br>Safety Issue? No</td>
</tr>
<tr>
<th>Secondary outcome</th><td>Measure: Changes in Sexual Functioning Questionnaire at Weeks 1, 4, 12, 16, and 24<br>Time Frame: Day 1 and Weeks 1, 4, 12, 16, and 24<br>Safety Issue? No</td>
</tr>
<tr>
<th>Secondary outcome</th><td>Measure: Change from baseline in Cuestionario Sevilla at Weeks 1, 4, 12, 16, and 24<br>Time Frame: Day 1 and Weeks 1, 4, 12, 16, and 24<br>Safety Issue? No</td>
</tr>
<tr>
<th>Secondary outcome</th><td>Measure: Change from baseline in Modified Resource Utilization Questionnaire (RUQ) scores at Weeks 3, 4, 6, 10, 12, 16, and 24<br>Time Frame: Day 1 and Weeks 3, 4, 6, 10, 12, 16, and 24<br>Safety Issue? No</td>
</tr>
<tr>
<th>Secondary outcome</th><td>Measure: Laboratory tests and electrocardiogram at Week 24<br>Time Frame: Screening and Week 24<br>Safety Issue? Yes</td>
</tr>
<tr>
<th>Secondary outcome</th><td>Measure: Adverse events on Day 1 and Weeks 1, 2, 3, 4, 6, 10, 12, 16, and 24<br>Time Frame: Day 1 and Weeks 1, 2, 3, 4, 6, 10, 12, 16, and 24<br>Safety Issue? Yes</td>
</tr>
<tr>
<th>Secondary outcome</th><td>Measure: Change from baseline in Clinical Global Impressions-Severity (CGI-S) scale scores at Weeks 1, 2, 3, 4, 6, 10, 12, 16, and 24<br>Time Frame: Day 1 and Weeks 1, 2, 3, 4, 6, 10, 12, 16, and 24<br>Safety Issue? No</td>
</tr>
<tr>
<th>Secondary outcome</th><td>Measure: Clinical Global Impressions-Improvement (CGI-I) scale scores at Weeks 1, 2, 3, 4, 6, 10, 12, 16, and 24<br>Time Frame: Day 1 and Weeks 1, 2, 3, 4, 6, 10, 12, 16, and 24<br>Safety Issue? No</td>
</tr>
<tr>
<th>Secondary outcome</th><td>Measure: Change from baseline in Positive and Negative Syndrome Scale (PANSS) total scores and negative subscale scores at Weeks 4, 10, 12, 16, and 24<br>Time Frame: Day 1 and Weeks 4, 10, 12, 16, and 24<br>Safety Issue? No</td>
</tr>
<tr>
<th>Secondary outcome</th><td>Measure: Barnes Akathisia Scale (BAS) and Abnormal Involuntary Movements Scale (AIMS) scores at Weeks 4, 10, 12, 16, and 24<br>Time Frame: Day 1 and Weeks 4, 10, 12, 16, and 24<br>Safety Issue? Yes</td>
</tr>
<tr>
<th>Condition</th><td>
         Schizophrenia
      </td>
</tr>
<tr>
<th>Arm/Group</th><td>
<div>Arm Label: Arm A      
            &nbsp; &nbsp; &nbsp; &nbsp;
        Experimental</div>
<p></p>
</td>
</tr>
<tr>
<th>Arm/Group</th><td>
<div>Arm Label: Arm B      
            &nbsp; &nbsp; &nbsp; &nbsp;
        Active Comparator</div>
<p></p>
</td>
</tr>
<tr>
<th>Intervention</th><td>
<div>Drug: Ziprasidone
            &nbsp; &nbsp; &nbsp; &nbsp;
            Arm Label: Arm A</div>
<p>Initial dose of 40 mg capsules twice daily on Days 1-3; dose could be flexibly changed within the range of 40 to 80 mg twice daily for the remainder of the study; treatment duration was 24 weeks.</p>
</td>
</tr>
<tr>
<th>Intervention</th><td>
<div>Drug: Risperidone
            &nbsp; &nbsp; &nbsp; &nbsp;
            Arm Label: Arm B</div>
<p>Initial dose of 10 mg once daily on Days 1-3; dose could be flexibly changed within the range of 3 to 9 mg twice daily for the remainder of the study; treatment duration was 24 weeks.</p>
</td>
</tr>
<tr>
<th>URL</th><td>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A1281065&amp;StudyName=A%20study%20comparing%20the%20safety%20and%20efficacy%20of%20ziprasidone%20and%20risperidone%20for%20the%20treatment%20of%20chronic%20schizophrenia</td>
</tr>
<tr>
<th>URL</th><td>http://www.clinicalstudyresults.org/drugdetails/?study_name=A1281065&amp;sort=c.company_name&amp;page=1&amp;drug_id=3690</td>
</tr>
<tr>
<th>See also</th><td>
<p>To obtain contact information for a study center near you, click here.</p>
</td>
</tr>
<tr>
<th>See also</th><td>
<p>Link to ClinicalStudyResults.org Posting</p>
</td>
</tr>
<tr>
<th class="section" colspan="2">
<h2>Recruitment Information</h2>
</th>
</tr>
<tr>
<th>Status</th><td>Terminated</td>
</tr>
<tr>
<th>Start date</th><td>
         2003-06
      </td>
</tr>
<tr>
<th>Last follow-up date</th><td>
         2003-12
      
      (Actual)
  </td>
</tr>
<tr>
<th>Criteria</th>
</tr>
<tr>
<td colspan="2" class="bigdent">
<p>Inclusion Criteria:<br> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- Diagnosis of schizophrenia<br> &nbsp;- CGI-S score of 4 or less at baseline<br> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Exclusion Criteria:<br> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- Concurrent antipsychotic treatment<br> &nbsp;- Treatment with antidepressants or mood stabilizers within 2 weeks of randomization<br> &nbsp;- Acute exacerbation of schizophrenia within 3 months of baseline</p>
</td>
</tr>
<tr>
<th>Gender</th><td>
            Both
         </td>
</tr>
<tr>
<th>Minimum age</th><td>18 Years</td>
</tr>
<tr>
<th>Maximum age</th><td>70 Years</td>
</tr>
<tr>
<th>Healthy volunteers</th><td>No</td>
</tr>
<tr>
<th class="section" colspan="2">
<h2>Administrative Data</h2>
</th>
</tr>
<tr>
<th>Organization name</th><td>Pfizer</td>
</tr>
<tr>
<th>Organization study ID</th><td>A1281065</td>
</tr>
<tr>
<th>Sponsor</th><td>
               Pfizer
            </td>
</tr>
<tr>
<th>Health Authority</th><td>
               Spain: Spanish Agency For Medicinal  Products And Medical Devices
         </td>
</tr>
</table><div class="navBottom"><div class="navBottomLine" style="background-image: url(/archive/ctgov_logo_ttm.gif)">&#160;</div><div class="navBottomLinks">&#160;</div></div></body>
</html>
